GlaxoSmithKline Buyback Hopes Rise After $1.7 Billion Quest Diagnostics Inc. Sale

February 2, 2011 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

LONDON, Feb 2 (Reuters) - Expectations that GlaxoSmithKline (GSK.L) will restart a share buyback programme in 2011 have risen with the sale of its stake in Quest Diagnostics (DGX.N) for some $1.7 billion, or $1.1 billion after tax.

Twitter
LinkedIn
Facebook
Email
Print

Mergers & acquisitions Europe

GSK